A panel of experts, including HIV+Hep’s Carl Schmid, shares thoughts and advice for the management and uptake of HIV PrEP therapy.
read more
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – episode 16 Overcoming HIV PrEP access barriers with advocacy groups
Carl Schmid shares insight on the use of advocacy groups to help patients overcome barriers to access for HIV PrEP therapy.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 15: Improving access and uptake of HIV PrEP
Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 14: COVID-19’s effect on access to HIV PrEP therapy
Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 12: Unmet needs for USPSTF guidelines for HIV PrEP
Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.